ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1292

What Is the Effect of TNF Inhibitors on Employment Status in Rheumatoid Arthritis Patients and What Are the Predictors of Progression to Unemployment?

Andrew Chow1, Regan Arendse2, Wojciech Olszynski2, John Kelsall3, Milton F. Baker4, William G Bensen5, Philip Baer6, Anna Jaroszynska7, Denis Choquette8, Suneil Kapur9, Jacqueline Stewart10, Emmanouil Rampakakis11,12, Eliofotisti Psaradellis12, Francois Nantel13, Susan Otawa14, Cathy Tkaczyk14, Allen J Lehman14 and Karina Maslova13, 1University of Toronto/McMaster University, Mississauga, ON, Canada, 2University of Saskatchewan, Saskatoon, SK, Canada, 3Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 4VIHA, Victoria, BC, Canada, 5St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 6Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, 7Private Practice, Burlington, ON, Canada, 8Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 9Rheumatology, University of Ottawa, Ottawa, ON, Canada, 10Penticton Regional Hospital, Penticton, BC, Canada, 11JSS Medical Research, St-Laurent, QC, Canada, 12JSS Medical Research, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Anti-TNF therapy and rheumatoid arthritis (RA), Employment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease which has been associated with an increased incidence of disability and unemployment over time. The aim of this analysis was to evaluate the prevalence of unemployment due to work disability in RA patients initiating treatment with infliximab (IFX) or golimumab (GLM) and to identify determinants of disability.

Methods:

BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, AS, or PsA with IFX or GLM as first biologics or after having been treated with a biologic for <6 months. Data were obtained from RA patients treated with IFX (2002-2014) or GLM (2010-2014). Between employment group differences were assessed for statistical significance with the independent samples t-test or the chi-square. Time to employment and time to unemployment were assessed with the Kaplan-Meier (KM) estimator of the survival function. Cox regression was used to identify predictors of time to unemployment.

Results:

A total of 581 RA patients were included; 374 (64.4%) employed and 207 (35.6%) unemployed due to disability. The following baseline parameters were associated with significantly increased likelihood of being unemployed due to disability: female vs. male gender (40.1% vs. 27.6%; P=0.006), earlier enrolment period (2002-05 vs. 2006-09 vs. 2010-14: 49.3% vs. 30.5% vs. 22.4%; P<0.001), insurance type (provincial vs. private vs. both: 54.9% vs. 23.8% vs. 20.0%; P<0.001), older age (P=0.033), and increased disease activity as evidenced by the higher DAS28 (P<0.001), SJC (P<0.001), TJC (P<0.001), HAQ (P<0.001), MDGA (P<0.001), PtGA (P<0.001), CDAI (P<0.001), SDAI (P<0.001), pain (P<0.001), and ESR (P<0.001).

Among disabled patients, 10.1% were able to return to work upon treatment with TNF a mean KM-based duration of 119.5 months from baseline; whereas 6.4% of employed patients became disabled (2002-05 vs. 2006-09 vs. 2010-14: 7.0% vs. 10.1% vs. 1.7%; P=0.021) with a mean time to unemployment of 113.4 months. Multivariate survival analysis showed that, upon adjusting for enrolment period, higher baseline HAQ [HR (95%CI): 3.59 (1.64, 7.87), P=0.001], and higher baseline SJC [HR (95%CI): 1.09 (1.02, 1.16), P=0.011] were significant predictors of unemployment due to disability.

Conclusion:

A significant proportion of RA patients are unemployed due to disability in Canada. At anti-TNF initiation, work disability was associated with higher disease activity, female gender, earlier enrolment period, and provincial insurance.  Increased HAQ and higher SJC were significant predictors of progression to unemployment highlighting the importance of early anti-TNF initiation in order to prevent work disability. Anti-TNF treatment was effective in enabling a considerable portion of disabled patients to return to employment.


Disclosure: A. Chow, Janssen Inc., 5; R. Arendse, Janssen Inc., 5; W. Olszynski, Janssen Inc., 5; J. Kelsall, Janssen Inc., 5; M. F. Baker, Janssen Inc., 5; W. G. Bensen, Janssen Inc., 5; P. Baer, Janssen Inc., 5,AbbVie, 5,Amgen, 5,BMS, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5; A. Jaroszynska, Janssen Inc., 5; D. Choquette, Janssen Inc., 5,AbbVie, 5,Amgen, 5,Celgene, 5,BMS, 5,Pfizer Inc, 5; S. Kapur, Janssen Inc., 5; J. Stewart, Janssen Inc., 5; E. Rampakakis, JSS, 3; E. Psaradellis, JSS Medical Research, 3; F. Nantel, Janssen Inc., 3; S. Otawa, Janssen Inc., 3; C. Tkaczyk, Janssen Inc., 3; A. J. Lehman, Janssen Inc., 3; K. Maslova, Janssen Inc., 3.

To cite this abstract in AMA style:

Chow A, Arendse R, Olszynski W, Kelsall J, Baker MF, Bensen WG, Baer P, Jaroszynska A, Choquette D, Kapur S, Stewart J, Rampakakis E, Psaradellis E, Nantel F, Otawa S, Tkaczyk C, Lehman AJ, Maslova K. What Is the Effect of TNF Inhibitors on Employment Status in Rheumatoid Arthritis Patients and What Are the Predictors of Progression to Unemployment? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/what-is-the-effect-of-tnf-inhibitors-on-employment-status-in-rheumatoid-arthritis-patients-and-what-are-the-predictors-of-progression-to-unemployment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-is-the-effect-of-tnf-inhibitors-on-employment-status-in-rheumatoid-arthritis-patients-and-what-are-the-predictors-of-progression-to-unemployment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology